| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP and GC
1 company
Glenn Baity last filed a Form 4 in April 2018, as EVP and GC at ACAD. Glenn Baity's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 83,734 shares of ACAD. The ACAD filings lean toward selling, a net 339,651 shares.
Glenn Baity has 22 Form 4 filings on record from March 2015 to April 2018, all as EVP and GC at Acadia Pharmaceuticals (ACAD), 2015–2018.
The 48 reported transactions were 28 option exercises, 15 open-market sales and 5 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $11.3M.
The largest open-market sale was 74,321 shares of ACAD at an average $30.14 on January 2, 2018, about $2.2M.
Shares as reported in the last Form 4 for each company; the most recent is from April 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 29, 2018 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sell | 36,558 | $32.39 | $1,184,055.13 | -30.4% | |
| Jan 2, 2018 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 74,321 | $30.14 | $2,240,138.99 | -51.5% | |
| Oct 5, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 37,500 | $40.91 | $1,534,042.50 | -35.0% | |
| Aug 30, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 26,507 | $34.87 | $924,314.99 | -28.2% | |
| Aug 9, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 14,322 | $34.88 | $499,534.17 | -15.6% | |
| Jul 20, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 38,097 | $30.00 | $1,142,910.00 | -34.9% | |
| Jun 22, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 1,903 | $30.00 | $57,090.76 | -2.3% | |
| Feb 14, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 26,365 | $39.66 | $1,045,517.26 | -28.2% | |
| Feb 1, 2017 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 31,078 | $35.15 | $1,092,382.38 | -31.7% | |
| Dec 27, 2016 | ACAD Acadia Pharmaceuticals Inc | EVP and GC | Sale+OE | 9,800 | $30.46 | $298,473.70 | -12.0% |